**Sir,**

*EGFR* and *KRAS* mutations occur mutually exclusively in NSCLC, suggesting functional redundancy ([@bib6]; [@bib15]; [@bib17]; [@bib18]). However, they predict contrasting response rates to tyrosine-kinase inhibitors (TKIs) -- while *EGFR* mutation predicts longer progression-free survival rate ([@bib9]; [@bib12]; [@bib3]; [@bib2]), adverse prognosis is associated with patients harbouring *KRAS* mutations ([@bib10]; [@bib5]). The recently reported co-occurrence of *KRAS* and *EGFR* activating mutations ([@bib7]) in 30 of 5125 patients raises questions about the relative values of *EGFR* and *KRAS* mutation status as predictors of outcome in NSCLC. This has obvious implications for routine *KRAS* testing in this disease, potentially precluding EGFR TKI therapy from some patients, similar to the current practice in colorectal cancer ([@bib8]).

*EGFR* mutations occur less frequently among Caucasians (10--15%) compared to East Asians (30--60%) ([@bib9]; [@bib14]) in contrast to *KRAS* mutations for which the situation is opposite -- Caucasians *vs* East Asians, 25--50% *vs* 5--15%, respectively ([@bib10]; [@bib16]). We recently reported an intermediate frequency of *EGFR* mutations (23%) in a study involving 907 Indian NSCLC patients ([@bib2]). In a smaller study at our centre there was 74% response to TKI among patients with tumours having *EGFR* mutations compared to 5% in those with wild-type *EGFR* ([@bib13]). We performed directed sequencing of *KRAS* exons 2 and 3 in 86 patients from the same cohort and correlated its status with outcome after treatment with EGFR TKI (see [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). There were 15 patients with *KRAS G12C* and 1 patient with *KRAS G12V* mutation for an overall mutation rate of 18.6%. Three of these 86 patients had coincident *KRAS* G12C and *EGFR* Exon-19 Del (E746-A750) mutations ([Table 1](#tbl1){ref-type="table"}), which were independently validated in each of the three samples by four orthogonal technologies (Sequenom Mass Array genotyping, Taqman Real Time PCR, Sanger Sequencing and SNaPShot PCR; see [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). All these three patients had partial response to EGFR TKI. However, only 1 of the remaining 13 patients with *KRAS* mutation had partial response and his tumour had wild-type *EGFR* with unknown copy number. This is consistent with previous studies: response to EGFR TKI in one of five patients harbouring *KRAS* mutation with unknown *EGFR* copy number or mutation status ([@bib19]); 1 response in 20 *KRAS* mutant patients who also harboured *EGF*R amplification but not *EGFR* mutation ([@bib4]); and response to gefitinib in three of five patients with coincident *EGFR* and *KRAS* mutations ([@bib1]). Furthermore, it has been shown that when *KRAS* and *EGFR* mutations are coincident in the same tumour, the genetic lesion in the latter is almost exclusively in exon-19, with virtually no occurrence of exon-21 abnormalities ([@bib7]). This was also true in all three cases in our series with coincident *EGFR* and *KRAS* mutations. Of note, mutations in exon-19 have been shown to predict a higher response to EGFR TKI than those in exon-21 ([@bib11]).

In summary, these data suggest that NSCLC patients with *KRAS* mutations are unlikely to respond to EGFR TKI therapy in the absence of coincident *EGFR* alterations. Therefore additional *KRAS* molecular testing may not add predictive value in selecting patients for EGFR TKI therapy and cannot be routinely recommended.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
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###### 
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###### 
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###### *EGFR* and *KRAS* mutation co-occurrence in Indian NSCLC patients

  **Sample ID**    **EGFR mutation**   **KRAS mutation**   **Histology type**   **Gender**   **Smoking history**   **Response to gefitinib**
  --------------- ------------------- ------------------- -------------------- ------------ --------------------- ---------------------------
  LB-21               Exon-19 Del            G12C            Adenocarcinoma       Female             No                       PR
  LB-69               Exon-19 Del            G12C            Adenocarcinoma       Female             No                       PR
  LB-117              Exon-19 Del            G12C            Adenocarcinoma       Female             No                       PR

Abbreviation: PR=partial response.
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